The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

amplobiotechnology.com

Founded Year

2019

Stage

Seed VC | Alive

Total Raised

$2.24M

Last Raised

$2.24M | 7 mos ago

About Amplo Biotechnology

Amplo Biotechnology is a gene therapy company focused on the neuromuscular junction.

Amplo Biotechnology Headquarter Location

2637 East Atlantic Boulevard

Pompano Beach, Florida, 33062,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Amplo Biotechnology News

Amplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction Disorders

Oct 7, 2021

Amplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction Disorders NEW YORK, October 6, 2021-- Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for diseases affecting the neuromuscular junction, today announced the successful closing of an undisclosed Series Seed financing. The Seed round was led by BioBrit, LLC., joined by Casdin Capital, SeedFolio and small group of sophisticated, biotech angel investors. In conjunction with the financing, Dan Bradbury (BioBrit, LLC.) has been appointed Chair of the Board. It was also announced that Amplo was awarded a NIH Fast-Track Phase I/II SBIR grant for the development of AMP-101 gene therapy. The latest funding round will be used to advance AMP-101, an AAV carrying Dok-7, to large scale manufacturing and to complete IND-enabling studies. AMP-101 was invented as a means to treat Dok-7 congenital myasthenic syndrome. AMP-101 has also shown to revert age-related loss in muscle function by improving the neuromuscular junction and decreasing denervation in mice. AMP-101 has also shown to increase survival and functional benefits in mouse models of Amyotrophic Lateral Sclerosis and Emery-Dreyfuss muscular dystrophy. Amplo secured FDA orphan drug designation for AMP-101 in January 2020. Amplo, plans to begin clinical trials in Dok-7 congenital myasthenic syndrome in 2023, with aims to move into other neuromuscular conditions once initial safety and efficacy are demonstrated. "When we think about AMP-101, we see the potential to treat many neuromuscular diseases with a single gene therapy. The closing of the Seed financing will allow us to rapidly execute on a plan that has received FDA and MHRA input," said Patricio Sepulveda Ph.D. MBA, CEO of Amplo Biotechnology. In addition, AMP-101, Amplo is developing other AAVs to treat diseases of the neuromuscular junction. About Amplo Biotechnology Amplo is a late preclinical AAV gene therapy company focused on developing therapies for congenital myasthenic syndromes and conditions of the neuromuscular junction.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.